Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The participants were divided into two groups, with half receiving weekly low-dose injections of semaglutide (Ozempic and Wegovy), a GLP-1 agonist, and the other half getting a placebo shot.

of whom 419 received a GLP-1-based medication and 240 received placebo (mean age, 41.7 years; 75% women). Five trials used medication doses indicated for obesity treatment, and the remaining four ...